Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Nov 3, 2020
Date Accepted: Dec 8, 2020
Date Submitted to PubMed: Dec 10, 2020
Artificial intelligence can predict the mortality of COVID-19 patients at the admission time using routine blood samples
ABSTRACT
Background:
COVID-19, which is accompanied by acute respiratory distress, multiple organ failure, and death, has spread worldwide much faster than previously thought. However, at present, it has limited treatments.
Objective:
To overcome this issue, we developed an artificial intelligence (AI) model of COVID-19, named EDRnet, to predict in-hospital mortality using a routine blood sample at the time of hospital admission.
Methods:
We selected 28 blood biomarkers and used the age and gender information of patients as model inputs. To improve the mortality prediction, we adopted an ensemble approach combining a deep neural network and random forest model. We trained our model with a database of blood samples from 361 COVID-19 patients in Wuhan, China, and applied it to 106 COVID-19 patients in three Korean medical institutions.
Results:
In the testing datasets, EDRnet provided high sensitivity (100%), specificity (91.35%), and accuracy (91.51%). To extend the number of patient data, we developed a web application (http://beatcovid19.ml/), where anyone can access the model to predict the mortality and can register his or her own blood laboratory results.
Conclusions:
Our new AI model, EDRnet, accurately predicts the mortality rate for COVID-19. It is publicly available and aims to help healthcare providers fight COVID1-19 and improve patients’ outcome.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.